undamentalytics Newsletter
Sign in

Nuwellis, Inc. (NUWE) stock

Add to watchlist

Add holding +

NASDAQ: NUWE Nasdaq Health Care Equipment Next results ~November 11, 2026

C Fundamentals grade

Nuwellis, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

Under review: share count (1m) is 0.16x the cover-page count (4m).

Price vs value

Under review: share count (1m) is 0.16x the cover-page count (4m). We'll show the comparison once resolved.

Nuwellis, Inc. valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Funds5 adding, 0 cuttingOf 0 active managers that changed their stake, 0 added; quarter to June 30, 2026Fund buyers and sellers

Value diary

Our note on each quarter Nuwellis files

Where Nuwellis stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $9m, up 8.4% on a year earlier, against a decline of 0.2% a quarter earlier. Free-cash-flow margin fell to -139.7% from -103.6% a year earlier. Operating margin narrowed to -142.9% from -118.8%. It passes 2 of our 2 financial-health checks.

Our model value for Nuwellis is under review, so past values are not shown until it is resolved.

Source: 10-Q filed August 13, 2026 on SEC EDGAR · Financials · Valuation

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~November 11, 2026 (estimated)

Nuwellis, Inc.'s trailing-twelve-month revenue grew 8.4% year on year, with a free-cash-flow margin of -139.7%. Where it stands out: stock pay as % of revenue of 1.0% ranks 8 of 123 health care equipment companies we cover. Where it lags: free-cash-flow margin of -139.7% ranks 106 of 128 health care equipment companies we cover.

Current signal Free cash flow diverging from earnings: TTM free cash flow fell 46.1% while net income grew 22.9%: a 69pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Growth speeding up. The growth rate is 8.6 points higher than a quarter earlier.
  • Net cash. Cash exceeds long-term debt by $0.0bn.

Things to watch

  • Results due soon. Results are expected around 11 November; the share price can move sharply on the day.
  • Loss-making. Operating margin is -142.9%: costs exceed revenue.
  • Margins narrowing. Operating margin is down 24.0 points on a year ago.
  • Burning cash. Free cash flow was -139.7% of revenue over the last 12 months.
  • Share dilution. Diluted shares rose 5.4% in a year.
  • Volatile shares. Over the past year the shares showed annualised volatility of 224% and a beta of 4.5 against the S&P 500.

Latest results: FY2026 Q2

Filed August 13, 2026
Earnings per share
-$658.35 against an average estimate of -$315.00: missed by 109.0%
Revenue
$2m, up 14.1% on a year earlier
Share reaction
-7.1% in the first session after the results on August 13, 2026, against +0.5% for the S&P 500
Next report
November 11, 2026

Nuwellis' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-8.8%
  • 1 week+60.4%
  • 1 month-16.6%
  • This year-99.1%
  • 1 year-99.4%
  • 5 years-100.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$9M
Operating margin
-142.9%
Net margin
-125.6%

Growth

Revenue growth
+8.4%
Change in growth rate
+8.6 pts

Cash

Free cash flow (TTM)
-$12.6M
FCF margin
-139.7%
Stock pay % of revenue
1.0%

Earnings

Last results
August 13, 2026
Next results (est.)
November 11, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Governance
  2. Announcement
  3. Results
  4. Agreement
  5. Shareholder vote

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Nuwellis, Inc. valuation models and calculator

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: share count (1m) is 0.16x the cover-page count (4m): held for review.

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025
Share price$15752961589248.00$4084100923392.00$67290425856.00$9529569216.00$1194669000.00$322745832.00$52787700.00$4963896.00$268569.00$14685.30$548.10
Market value$4126.54tn$1169.03tn$28.02tn$4.17tn$524.6bn$144.3bn$24.7bn$5.8bn$306m$464m$378m
+ Net debt (− = net cash)−$15m$3m−$16m−$5m−$1m−$14m−$9m−$18m−$4m−$5m−$1m
Enterprise value$4126.54tn$1169.03tn$28.02tn$4.17tn$524.6bn$144.2bn$24.7bn$5.8bn$303m$459m$377m
Multiples
Price / sales n/mn/mn/mn/mn/mn/mn/mn/m34.6x53.1x45.7x
Price / earnings ———————————
Price / free cash flow ———————————
EV / EBITDA ———————————

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

33 /100

Weak moat

How hard Nuwellis's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 0 / 20

    Cash operating profit has been a median -79.6% of total assets over 5 years.

  • Pricing power 17 / 20

    Gross margin has been a median 59.1%, moving by 5.2 percentage points (standard deviation) across 6 years.

  • Durability 10 / 20

    Operating margin has been a median -236.2%; its worst year was -472.4%.

  • Cash conversion 0 / 20

    Free cash flow was positive in 0 of 10 years, at a median -222.5% of revenue.

AI disruption exposure: Low. In this industry, the business rests on physical assets, regulated networks or products AI itself depends on.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: November 11, 2026, before the open.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current — — $18m +115%

Earnings against estimates

Quarter toEstimateActualSurprise
Mar 2026 −$315.00 −$658.35 −109.0%
Dec 2025 −$491.40 −$472.50 +3.9%

Adjusted EPS as companies report it, against the average analyst estimate.

Positioning

Short interest
2.5%
of tradable shares
Days to cover
0.03
at average volume
Short interest, 1 month
+135%
to October 15, 2026
Held by institutions
2%
of shares
Held by insiders
3.7%
of shares
Employees
38
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
NUWE−84%−91%−95%−95%−96%−99%
Industry peers (median)−7%−37%−8%−19%−16%−13%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
NUWE17%25%17%25%33%18%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
NUWE−89%−95%−96%−96%−97%−100%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 100% from November 3, 2015 to October 23, 2026. Getting back needed a 980108732833523% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.88 – $1319.85
From 52-week high
−99.6%
vs 50-day average
−20.8%
vs 200-day average
−97.8%
Volatility (1 year)
224%
Beta vs S&P 500
4.51

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
4 up, 8 down
typical move ±14.3%
After a week
2 up, 10 down
typical move ±16.2%
After a month
1 up, 11 down
typical move ±37.3%
Results releasedNext dayS&P 500 next day5 days21 days
August 13, 2026 −7.1% +0.5% −20.6% −43.3%
May 12, 2026 −1.0% +0.4% −5.8% −86.5%
March 10, 2026 +4.7% −0.3% −16.3% −16.3%
November 12, 2025 −11.9% −1.6% −18.3% −18.0%
August 14, 2025 +0.7% −0.2% −3.8% −14.5%
May 13, 2025 −3.0% +0.8% −3.0% −68.7%
March 11, 2025 −6.3% −0.3% −11.9% −31.7%
November 12, 2024 −4.9% −0.3% −34.6% −41.0%
November 1, 2024 +63.4% +0.2% +5.2% −25.6%
August 13, 2024 −14.3% +2.0% −27.2% −46.4%
May 7, 2024 +52.9% +0.1% +35.3% +29.4%
March 6, 2024 −2.0% +1.5% −12.0% −26.0%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Nuwellis, Inc. in five measures

Fundamentals grade C
Growth Profitability Cash Balance sheet

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Nuwellis, Inc.
$8M $8.5M $9M $9.5M FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue (TTM), FY23 Q3: $8.7M Revenue (TTM), FY23 Q4: $8.9M Revenue (TTM), FY24 Q1: $8.9M Revenue (TTM), FY24 Q2: $9M Revenue (TTM), FY24 Q3: $9M Revenue (TTM), FY24 Q4: $8.7M Revenue (TTM), FY25 Q1: $8.8M Revenue (TTM), FY25 Q2: $8.3M Revenue (TTM), FY25 Q3: $8.2M Revenue (TTM), FY25 Q4: $8.3M Revenue (TTM), FY26 Q1: $8.8M Revenue (TTM), FY26 Q2: $9M $9M

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue (TTM)
FY23 Q3 $8.7M
FY23 Q4 $8.9M
FY24 Q1 $8.9M
FY24 Q2 $9M
FY24 Q3 $9M
FY24 Q4 $8.7M
FY25 Q1 $8.8M
FY25 Q2 $8.3M
FY25 Q3 $8.2M
FY25 Q4 $8.3M
FY26 Q1 $8.8M
FY26 Q2 $9M
Revenue growth, TTM YoY Nuwellis, Inc.
-10% -5% 0% 5% 10% 15% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Revenue growth, TTM YoY, FY23 Q3: 10.3% Revenue growth, TTM YoY, FY23 Q4: 3.8% Revenue growth, TTM YoY, FY24 Q1: 5.4% Revenue growth, TTM YoY, FY24 Q2: 8.5% Revenue growth, TTM YoY, FY24 Q3: 3.7% Revenue growth, TTM YoY, FY24 Q4: -1.4% Revenue growth, TTM YoY, FY25 Q1: -1.2% Revenue growth, TTM YoY, FY25 Q2: -7.7% Revenue growth, TTM YoY, FY25 Q3: -8.9% Revenue growth, TTM YoY, FY25 Q4: -5.4% Revenue growth, TTM YoY, FY26 Q1: -0.2% Revenue growth, TTM YoY, FY26 Q2: 8.4% 8.4%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q3 10.3%
FY23 Q4 3.8%
FY24 Q1 5.4%
FY24 Q2 8.5%
FY24 Q3 3.7%
FY24 Q4 -1.4%
FY25 Q1 -1.2%
FY25 Q2 -7.7%
FY25 Q3 -8.9%
FY25 Q4 -5.4%
FY26 Q1 -0.2%
FY26 Q2 8.4%
Operating margin (TTM) Nuwellis, Inc.
-300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 Operating margin (TTM), FY23 Q3: -214.6% Operating margin (TTM), FY23 Q4: -198.9% Operating margin (TTM), FY24 Q1: -185.8% Operating margin (TTM), FY24 Q2: -153.4% Operating margin (TTM), FY24 Q3: -136.0% Operating margin (TTM), FY24 Q4: -125.7% Operating margin (TTM), FY25 Q1: -105.8% Operating margin (TTM), FY25 Q2: -118.8% Operating margin (TTM), FY25 Q3: -135.3% Operating margin (TTM), FY25 Q4: -134.3% Operating margin (TTM), FY26 Q1: -143.8% Operating margin (TTM), FY26 Q2: -142.9% -142.9%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q3 -214.6%
FY23 Q4 -198.9%
FY24 Q1 -185.8%
FY24 Q2 -153.4%
FY24 Q3 -136.0%
FY24 Q4 -125.7%
FY25 Q1 -105.8%
FY25 Q2 -118.8%
FY25 Q3 -135.3%
FY25 Q4 -134.3%
FY26 Q1 -143.8%
FY26 Q2 -142.9%
FCF margin (TTM) Nuwellis, Inc.
-300% -200% -100% 0% FY23 Q3 FY24 Q2 FY25 Q1 FY26 Q2 FCF margin (TTM), FY23 Q3: -214.0% FCF margin (TTM), FY23 Q4: -204.0% FCF margin (TTM), FY24 Q1: -167.0% FCF margin (TTM), FY24 Q2: -136.8% FCF margin (TTM), FY24 Q3: -120.9% FCF margin (TTM), FY24 Q4: -110.4% FCF margin (TTM), FY25 Q1: -105.8% FCF margin (TTM), FY25 Q2: -103.6% FCF margin (TTM), FY25 Q3: -115.2% FCF margin (TTM), FY25 Q4: -131.8% FCF margin (TTM), FY26 Q1: -131.2% FCF margin (TTM), FY26 Q2: -139.7% -139.7%

Source: SEC EDGAR filings. Retrieved October 29, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q3 -214.0%
FY23 Q4 -204.0%
FY24 Q1 -167.0%
FY24 Q2 -136.8%
FY24 Q3 -120.9%
FY24 Q4 -110.4%
FY25 Q1 -105.8%
FY25 Q2 -103.6%
FY25 Q3 -115.2%
FY25 Q4 -131.8%
FY26 Q1 -131.2%
FY26 Q2 -139.7%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Financial statements

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Jun 2026
Income
Revenue 0 0 0 0 1 4 5 6 7 8 9 9 9 8 9
Gross profit — — — — — 1 1 3 4 4 5 5 6 5 6
EBITDA −15 −23 −26 −26 −15 −14 −17 −18 −17 −19 −17 −17 −11 −11 −13
Operating income −15 −23 −26 −26 −16 −15 −17 −18 −17 −20 −17 −18 −11 −11 −13
Net income −14 −22 −26 −27 −16 −13 −17 −18 −16 −20 −15 −20 −11 −18 −11
Diluted EPS −$19174.67 −$16559.94 −$14623.11 −$101476.34 −$61808.10 −$60527.26 −$388.66 −$51446.04 −$39363.87 −$42110.12 −$12329.34 −$17711.16 −$353.30 −$25.39 —
Growth (year on year)
Revenue — — +400.0% −80.0% +>999% +175.6% +40.7% +10.3% +35.0% +6.5% +7.9% +3.8% −1.4% −5.4% +8.4%
Margins
Gross margin — — — — — 22.2% 26.6% 51.7% 54.5% 56.7% 55.7% 56.2% 64.9% 62.0% 69.7%
EBITDA margin — <−999% <−999% <−999% <−999% −395.2% −336.2% −324.2% −223.8% −240.3% −196.6% −194.8% −122.2% −131.9% −141.2%
Operating margin — <−999% <−999% <−999% <−999% −416.9% −340.9% −328.5% −228.8% −246.5% −201.0% −198.9% −125.7% −134.3% −142.9%
Net margin — <−999% <−999% <−999% <−999% −376.6% −340.8% −328.7% −212.8% −246.9% −170.0% −228.0% −127.7% −211.9% −125.6%
Free-cash-flow margin — <−999% <−999% <−999% <−999% −342.8% −295.3% −305.9% −226.7% −228.0% −178.8% −204.0% −110.4% −131.8% −139.7%
Cash flow
Cash from operations −13 −17 −23 −23 −16 −12 −15 −16 −17 −18 −15 −18 −10 −11 −12
Capital spending 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Free cash flow −13 −18 −23 −23 −16 −12 −15 −17 −17 −18 −15 −18 −10 −11 −13
Stock-based pay 1 3 3 2 1 0 2 2 1 1 1 1 0 0 0
Free cash flow after stock pay −14 −21 −26 −25 −17 −13 −17 −18 −18 −19 −16 −19 −10 −11 −13
Balance sheet
Cash 14 54 31 23 1 16 5 1 14 9 18 4 5 1 4
Total debt 0 0 0 8 4 0 0 0 0 0 0 0 0 0 0
Net debt (negative = net cash) −14 −54 −31 −15 3 −16 −5 −1 −14 −9 −18 −4 −5 −1 −4
Diluted shares — — — — — — — — — — — — — — —

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 2 checks passed · June 30, 2026
What it owns · $9m
Short-term assets $8mLonger-term assets $1m
What it owes, and who funded it · $11m
Short-term liabilities $4mLonger-term liabilities $7mShareholders' equity $-2m
  • Short-term assets cover short-term liabilities $8m of assets due within a year against $4m of liabilities due within a year.
  • Short-term assets cover long-term liabilities $8m short-term assets against $7m of longer-dated liabilities.
  • More cash than debt Cash or debt not separately reported. Not assessable.
  • Debt below 40% of shareholders' equity Equity or debt not reported. Not assessable.
  • Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
  • A year's operating cash flow covers at least 20% of debt Cash flow or debt not reported. Not assessable.
  • Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Nuwellis, Inc.'s latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

R&D spending
46.1%
of revenue
Sales & admin spending
166.4%
of revenue
Days sales outstanding
63 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in health care equipment
Last 12 months unless stated NUWE NNNN MLSS NMTC WOK XAIR Median
Revenue, last 12 months $9m $9m $9m $9m $10m $8m $99m
Revenue growth, last 12 months 8.4% 5.6% 3.7% 42.8% −14.4% 60.7% 9.2%
Revenue growth, 3-year average 2.8% — −1.9% 94.9% — 122.7% 13.5%
Revenue growth, latest quarter 14.1% — 22.3% 16.3% — 0.5% 10.2%
Gross margin 69.7% 87.2% 70.2% 55.6% 23.8% 4.2% 61.2%
Operating margin −142.9% 66.7% −43.6% −83.4% — −364.8% −8.5%
Operating margin, 3-year average −138.4% — −66.8% −160.3% — <−999% −17.9%
Net margin −125.6% 74.1% −44.0% −78.6% −10.9% −435.7% −12.0%
Cash from operations / revenue −138.3% −77.9% −6.8% −74.5% 63.4% −241.5% −1.9%
Free-cash-flow margin −139.7% — −7.0% −75.6% 49.9% −255.0% −3.9%
Free-cash-flow margin, 3-year average −126.7% — −53.1% −142.5% — <−999% −7.0%
Stock pay / revenue 1.0% — 10.3% 14.9% — 61.7% 6.1%
Change in share count 5.4% 3.3% 5.9% 41.1% 128.1% −99.0% 4.0%

Median of all 134 companies we cover in health care equipment. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

134 health care equipment companies
Measure Company Peer median Rank
Revenue growth Growth 8.4% 9.1% 71 of 129
Change in growth rate Growth +8.6pp -0.6pp 16 of 129
Gross margin Profitability 69.7% 61.9% 41 of 123
Operating margin Profitability -142.9% -8.3% 106 of 132
Net margin Profitability -125.6% -12.0% 107 of 133
Free-cash-flow margin Cash generation -139.7% -3.4% 106 of 128
Stock pay as % of revenue Cash generation 1.0% 6.1% 8 of 123
Days sales outstanding Balance sheet 63 days 57 days 76 of 118

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Who owns it

Funds buying and selling
Reported value
$63,941
Institutions reporting
5
Positions opened / closed
5 / 0

Top buyers and sellers, Q2 2026: 5 institutions bought and 0 sold ; the biggest buyer was Sabby Management, LLC (+16K shares) . See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Sabby Management, LLC $49,935 16K 78.1% —
UBS Group AG $13,466 4K 21.1% —
Tower Research Capital LLC (TRC) $421 0K 0.7% —
Morgan Stanley $107 0K 0.2% —
Sbi Securities Co., Ltd. $12 0K 0.0% —

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Nuwellis, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $0 0 trades by 0 insiders
Net ▲ $0 net buying

No open-market insider trades reported in the last 12 months.

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 11, 2026 estimated from the company's past filing pattern, not announced

  • August 13, 2026
  • May 12, 2026
  • March 10, 2026
  • November 12, 2025
  • August 14, 2025
  • May 13, 2025

Recent SEC filings

Data status

When each part of this page on Nuwellis, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Nuwellis, Inc. in brief

What does Nuwellis, Inc. do?
Nuwellis, Inc. is a US-listed company in the health care equipment industry. Its financial year ends in December.
What is Nuwellis, Inc.'s stock ticker?
Nuwellis, Inc. trades under the ticker NUWE on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Nuwellis, Inc.'s revenue, and how fast is it growing?
Over its most recent trailing twelve months, Nuwellis, Inc. reported revenue of $9M, 8.4% higher than a year earlier, according to its SEC filings.
What is Nuwellis, Inc.'s free cash flow?
Nuwellis, Inc.'s free-cash-flow margin is -139.7% of revenue over the trailing twelve months, ranking 106 of the 128 health care equipment companies we cover.
Who are Nuwellis, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Sabby Management, LLC, UBS Group AG and Tower Research Capital LLC (TRC). 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
What is Nuwellis, Inc.'s market cap?
On December 31, 2025, Nuwellis, Inc.'s market capitalisation was about $378M and net debt of -$1.1M. Market figures come from third-party market data and may be delayed.
Who are Nuwellis, Inc.'s competitors?
In our Health Care Equipment peer group, the companies closest to Nuwellis, Inc. are Anbio Biotechnology, Milestone Scientific Inc., Neuroone Medical Technologies Corp, Work Medical Technology Group LTD and Beyond Air, Inc. The side-by-side comparison below sets their revenue, margins and growth against Nuwellis, Inc.'s.
When is Nuwellis, Inc.'s next earnings date?
Around November 11, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Nuwellis, Inc. announces its own schedule.